Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients
CCA is an aggressive disease that requires early molecular testing of abundant biopsy tissue so not to delay second-line therapies, such as pemigatinib. Variability in treatment outcomes is expected.
Authors
- Vesa Väliaho (ORCID: https://orcid.org/0000-0002-3848-8916)
- Iben Spanggaard (ORCID: https://orcid.org/0000-0001-5925-2630)
Institutions
- University of Turku (FI)
- Turku University Hospital (FI)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-04-15
- DOI
- https://doi.org/10.2340/1651-226x.2025.42073
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Incyte
- Gentofte Hospital
- Rigshospitalet
- Turun Yliopistollinen Keskussairaala